levonorgestrel has been researched along with maraviroc in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA | 1 |
| Avenant, C; Dlamini, S; Enfield, K; Hapgood, JP; Kuipa, M | 1 |
1 review(s) available for levonorgestrel and maraviroc
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for levonorgestrel and maraviroc
| Article | Year |
|---|---|
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anti-HIV Agents; CCR5 Receptor Antagonists; Contraceptives, Oral; Cyclohexanes; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Ethinyl Estradiol; Female; HIV Infections; Humans; Lamivudine; Levonorgestrel; Male; Maraviroc; Midazolam; Middle Aged; Statistics as Topic; Triazoles; Zidovudine | 2008 |
2 other study(ies) available for levonorgestrel and maraviroc
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Maraviroc, tenofovir disoproxil fumarate and dapivirine, activate progesterone receptor B in the absence of progestogens.
Topics: Anti-HIV Agents; Binding, Competitive; Cell Line; Contraceptive Agents, Hormonal; HIV Infections; HIV-1; Humans; Immunologic Factors; In Vitro Techniques; Levonorgestrel; Maraviroc; Phosphorylation; Progesterone Congeners; Pyrimidines; Receptors, Progesterone; Tenofovir; Transcriptional Activation | 2020 |